CA
BMRN icon

Clearstead Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Clearstead Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.3K Sell
564
-4,439
-89% -$243K ﹤0.01% 1638
2026
Q1 		$283K Sell
5,003
-1,184
-19% -$69K ﹤0.01% 883
2025
Q4 		$368K Buy
6,187
+2,733
+79% +$149K ﹤0.01% 755
2025
Q3 		$187K Buy
3,454
+1,304
+61% +$74.6K ﹤0.01% 896
2025
Q2 		$118K Buy
2,150
+656
+44% +$38.6K ﹤0.01% 1016
2025
Q1 		$106K Buy
1,494
+1,243
+495% +$83.6K ﹤0.01% 985
2024
Q4 		$16.5K Hold
251
– – ﹤0.01% 1446
2024
Q3 		$17.6K Sell
251
-266
-51% -$22.2K ﹤0.01% 1456
2024
Q2 		$42.6K Buy
517
+266
+106% +$22.1K ﹤0.01% 1202
2024
Q1 		$20.2K Sell
251
-196
-44% -$17.5K ﹤0.01% 944
2023
Q4 		$43.1K Sell
447
-3,433
-88% -$304K ﹤0.01% 782
2023
Q3 		$343K Hold
3,880
– – 0.02% 347
2023
Q2 		$336K Buy
3,880
+231
+6% +$21.7K 0.02% 348
2023
Q1 		$355K Hold
3,649
– – 0.03% 314
2022
Q4 		$378K Hold
3,649
– – 0.03% 292
2022
Q3 		$309K Hold
3,649
– – 0.03% 302
2022
Q2 		$302K Hold
3,649
– – 0.02% 318
2022
Q1 		$281K Buy
3,649
+3,613
+10,036% +$302K 0.02% 358
2021
Q4 		$3K Buy
36
+18
+100% +$1.49K ﹤0.01% 1052
2021
Q3 		$1K Hold
18
– – ﹤0.01% 1183
2021
Q2 		$2K Sell
18
-20
-53% -$1.58K ﹤0.01% 1023
2021
Q1 		$3K Buy
38
+25
+192% +$2.04K ﹤0.01% 911
2020
Q4 		$1K Buy
+13
New +$1.03K ﹤0.01% 917

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Clearstead Advisors's BMRN Position: Q2 2026 in Review

Clearstead Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 89% in Q2 2026, selling an estimated $243K and leaving 564 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1638.

Clearstead Advisors first reported a position in BMRN in Q4 2020 and has held it in 23 quarters since. The position peaked at $378K in Q4 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Clearstead Advisors held 564 shares of BioMarin Pharmaceuticals worth $32.3K as of Q2 2026.
  • Clearstead Advisors sold 4,439 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $243K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1638 holding.
  • Clearstead Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Clearstead Advisors's BioMarin Pharmaceuticals position peaked at $378K in Q4 2022.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.